Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis

This study aimed to confirm changes in biomarkers of erythropoiesis and iron metabolism and serum fibroblast growth factor 23 (FGF-23) during darbepoetin-α treatment and then switching to the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat. A total of 28 patients on hemodialysis who...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Shunsuke, Saito, Tomohiro, Shibagaki, Keigo, Hirao, Keiichi, Yuza, Takatoshi, Tomosugi, Naohisa, Honda, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950357/
https://www.ncbi.nlm.nih.gov/pubmed/36823243
http://dx.doi.org/10.1038/s41598-023-30331-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950357/
https://www.ncbi.nlm.nih.gov/pubmed/36823243
http://dx.doi.org/10.1038/s41598-023-30331-6

Ejemplares similares